The Essential Role of Genetic Counseling in Inherited Thrombophilia

Seminars in Hematology

Volumn 44, Issue 2, 2007, Pages 126-129

  Lochhead, Paul ^a   Miedzybrodzka, Zosia ^b  

^a Clinical Genetics Centre   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CONTRACEPTIVE AGENT;

ARTICLE; DISEASE PREDISPOSITION; DRUG USE; GENE MUTATION; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; THROMBOPHILIA; VEIN THROMBOSIS;

BLOOD COAGULATION DISORDERS, INHERITED; CONTRACEPTIVES, ORAL, COMBINED; FEMALE; GENETIC COUNSELING; HUMANS; MASS SCREENING; RISK ASSESSMENT; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 34047266427     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.01.003     Document Type: Article

References (30)

1. Egeberg O. Thrombophilia caused by inheritable deficiency of blood antithrombin. Scand J Clin Lab Invest 17 (1965) 92
2. Heijboer H., Brandjes D.P., Buller H.R., Sturk A., and ten Cate J.W. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 323 (1990) 1512-1516
3. Bertina R.M., Koeleman B.P., Koster T., Rosendaal F.R., Dirven R.J., de Ronde H., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
4. Dahlback B., Carlsson M., and Svensson P.J. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 90 (1993) 1004-1008
5. Rees D.C., Cox M., and Clegg J.B. World distribution of factor V Leiden. Lancet 346 (1995) 1133-1134
6. Poort S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
7. Harper P.S. Practical Genetic Counseling (2004), Arnold, London
8. Human Genetics Commission. Inside Information: Balancing Interests in the Use of Personal Genetic Data (2002), Crown, London
9. Joint Committee on Medical Genetics. Consent and Confidentiality in Genetic Practice: Guidance on Genetic Testing and Sharing Genetic Information (2006), Royal College of Physicians, London
10. General Medical Council. Good Medical Practice (2006), General Medical Council, London
11. General Medical Council. Seeking Patients' Consent: The Ethical Considerations (1998), General Medical Council, London
12. Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 114 (2001) 512-528
13. College of American Pathologists Consensus Conference XXXVI. Diagnostic issues in thrombophilia. Arch Pathol Lab Med 126 (2002) 1277-1433
14. Sarasin F.P., and Bounameaux H. Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis. BMJ 316 (1998) 95-99
15. van den Belt A.G., Hutten B.A., Prins M.H., and Bossuy P.M. Duration of oral anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S-A decision analysis. Thromb Haemost 84 (2000) 758-763
16. Marchetti M., Pistorio A., and Barosi G. Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden-Cost-effectiveness analysis. Thromb Haemost 84 (2000) 752-757
17. Rosendaal F.R., Koster T., Vandenbroucke J.P., and Reitsma P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85 (1995) 1504-1508
18. De Stefano V., Martinelli I., Mannucci P.M., Paciaroni K., Chiusolo P., Casorelli, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 341 (1999) 801-806
19. Koeleman B.P., Reitsma P.H., and Bertina R.M. Familial thrombophilia: A complex genetic disorder. Semin Hematol 34 (1997) 256-264
20. van Boven H.H., Reitsma P.H., Rosendaal F.R., Bayston T.A., Chowdhury V., Bauer K.A., et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 75 (1996) 417-421
21. van Boven H.H., Vandenbroucke J.P., Briet E., and Rosendaal F.R. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. Blood 94 (1999) 2590-2594
22. Middeldorp S., Henkens C.M., Koopman M.M., van Pampus E.C., Hamulyak K., van der Meer J., et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 128 (1998) 15-20
23. Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism. Lancet 356 (2000) 182-183
24. Hille E.T., Westendorp R.G., Vandenbroucke J.P., and Rosendaal F.R. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 89 (1997) 1963-1967
25. Clinical Genetics Society. The genetic testing of children: Report of a Working Party of the Clinical Genetics Society (UK). J Med Genet 31 (1994) 785-797
26. Vandenbroucke J.P., Koster T., Briet E., Reitsma P.H., Bertina R.M., and Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344 (1994) 1453-1457
27. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR: Factor V Leiden: Should we screen oral contraceptive users and pregnant women? BMJ 313:1127-1130
28. British National Formulary 52 (2006), BMJ Publishing Ltd and RPS Publishing, London
29. Wu O., Robertson L., Twaddle S., Lowe G.D.O., Clark P., Greaves M., et al. Screening for thrombophilia in high-risk situations. Systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 10 (2006) 1-110
30. Lensen R., Rosendaal F., Vandenbroucke J., and Bertina R. Factor V Leiden: The venous thrombotic risk in thrombophilic families. Br J Haematol 110 (2000) 939-945